OxyContin Patent
MANHATTAN – A generic version of the blockbuster drug OxyContin did not infringe on Purdue Pharma’s patent, a federal judge ruled, siding with the patent invalidity defense put forward by Teva Pharmaceuticals.
MANHATTAN – A generic version of the blockbuster drug OxyContin did not infringe on Purdue Pharma’s patent, a federal judge ruled, siding with the patent invalidity defense put forward by Teva Pharmaceuticals.